The Swiss Cancer Center - Leman (SCCL) is an alliance against cancer forged between several academic and clinical institutions: the University Hospital of Lausnne (CHUV), the University Hospitals of Geneva (HUG), the University of Lausanne, the University of Geneva and the Swiss Federal Institute of Technology Lausanne (EPFL), as well as privileged partners (see below).[1]
| Established | 2016 |
|---|---|
Field of research | Oncology |
| Director | Prof. George Coukos, Prof. Douglas Hanahan, Prof. Pierre-Yves Dietrich |
| Address | Rue du Bugnon 1011 Lausanne |
| Location | Lausanne, Switzerland 46°31′31″N 6°38′27″E / 46.525305°N 6.640883°E |
| Affiliations | CHUV, UNIL, EPFL, University Hospitals of Geneva (HUG) and University of Geneva (UNIGE). |
| Website | sccl |
This alliance brings together, under a united and regional identity, all the specialists involved in the path from bench to bedside.[1] Focusing their efforts on emerging fields within oncology, the partner institutions intend to develop innovative strategies such as immunotherapy and precision oncology to achieve personalized and predictive medical strategies that will ultimately revolutionize patient care.[2]
The SCCL conducts its research in a network of laboratories located within its constituent institutions.
Executive committee
editThe SCCL Executive Committee is composed of the senior directors in oncology of its partner institutions:
- Professor George Coukos, Head of the Department of oncology UNIL CHUV
- Professor Douglas Hanahan, Director of the Swiss Institute for Experimental Cancer Research (ISREC) at EPFL
- Professor Pierre-Yves Dietrich, Head of the Department of oncology HUG UNIGE
The AGORA building
editThe Agora, the flagship building of the Swiss Cancer Centre - Leman (SCCL), embodies and puts into the practice the central vision of the SCCL has for cancer science and medicine. A FLASH radiotherapy device for treatment of cancers resistant to conventional treatments is developed together with CERN and THERYQ (Alcen Group) and will be installed at the CHUV. The first clinical trials are planned for 2025.[3][4]
Other
editIn 2016, the University Hospital of Lausanne inaugurated a cell production laboratory for cancer immunotherapy on the Biopôle campus (Épalinges).[5]
See also
editNotes and references
edit- ^ a b "A Lausanne, le centre de recherche sur le cancer ouvrira en 2018". Le Temps (in French). Retrieved 2018-10-08.
- ^ "L'Arc lémanique au cœur de la nouvelle révolution anticancer". Le Temps (in French). Retrieved 2018-10-08.
- ^ "CHUV, CERN and THERYQ join forces for a world first in cancer radiotherapy". The Greater Geneva Bern area. 2022-11-28. Retrieved 2023-03-08.
- ^ Dubouloz, Catherine (2016-09-29). "A Lausanne, le centre de recherche sur le cancer ouvrira en 2018". Le Temps (in French). Retrieved 2023-03-08.
- ^ (in French) Nathalie Jollien, "Nouveau laboratoire d'immunothérapie à Lausanne", Le temps, 15 September 2016 (page visited on 16 September 2016).
